PATENT CLAIM ANALYSIS

Application Number: 16101861
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "158100"]

Abstract:
Antibodies that bind the apple 2 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa are described.

Claim (Index 28):
A composition comprising an antibody or antigen binding fragment comprising:\n (i) a heavy chain (HC) having a variable domain comprising a heavy chain complementarity determining region (HC-CDR) 1 having the amino acid sequence shown in SEQ ID NO:7, a HC-CDR 2 having the amino acid sequence shown in SEQ ID NO:8, and a HC-CDR 3 having the amino acid sequence shown in SEQ ID NO:9 or 13, wherein optionally one or more of the HC-CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof; and (ii) a light chain (LC) having a variable domain comprising a light chain complementarity determining region (LC-CDR) 1 having the amino acid sequence shown in SEQ ID NO:10, a LC-CDR 2 having the amino acid sequence shown in SEQ ID NO:11, and a LC-CDR 3 having the amino acid sequence shown in SEQ ID NO:12, wherein optionally one or more of the LC-CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof; or (ii) a heavy chain (HC) having a variable domain comprising a heavy chain complementarity determining region (HC-CDR) 1 having the amino acid sequence shown in SEQ ID NO:1, an HC-CDR 2 having the amino acid sequence shown in SEQ ID NO:2, and an HC-CDR 3 having the amino acid sequence shown in SEQ ID NO:3, wherein optionally one or more of the HC-CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof; and (iii) a light chain (LC) having a variable domain comprising a light chain complementarity determining region (LC-CDR) 1 having the amino acid sequence shown in SEQ ID NO:4, a LC-CDR 2 having the amino acid sequence shown in SEQ ID NO:5, and a LC-CDR 3 having the amino acid sequence shown in SEQ ID NO:6, wherein optionally one or more of the LC-CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof wherein the antibody or antigen binding fragment is obtained from a host cell comprising a nucleic acid molecule encoding the HC and a nucleic acid molecule encoding the LC and a pharmaceutically acceptable carrier or diluent.

Metadata:
- Claim Count in Document: 122.0
- Percentile: 96.0
- Lexical Diversity: 1.09091
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15409607', '15619620', '16335133', '15906773', '15934526']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7557555634175493
- 35 USC 102 Novelty (BERT): 0.7264351484007356
- Combined Prediction Score: 0.752823521915868
- Mean Citation Score: 558.16293
- Max Citation Score: 887.4425699999997
- Similarity Product: 768.9834980995199

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test